Deferred Tax Assets, Gross of ArriVent BioPharma, Inc. from 31 Dec 2023 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary: ArriVent BioPharma, Inc. quarterly Deferred Tax Assets, Gross in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
ArriVent BioPharma, Inc. Deferred Tax Assets, Gross for the quarter ending 31 Dec 2025 was $109,270,000, a 59% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Gross, Quarterly (USD)

Deferred Tax Assets, Gross, YoY Quarterly Change (%)

ArriVent BioPharma, Inc. Quarterly Deferred Tax Assets, Gross (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$109,270,000	+$40,438,000	+59%	31 Dec 2025	10-K	05 Mar 2026	2025	FY
Q4 2024	$68,832,000	+$24,640,000	+56%	31 Dec 2024	10-K	05 Mar 2026	2025	FY
Q4 2023	$44,192,000			31 Dec 2023	10-K	03 Mar 2025	2024	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.